Background/Objectives: To examine the effects of betaine on serum lipid profile, plasma homocysteine concentration and hemostatic factors in healthy subjects. Subjects/Methods: Altogether, 63 volunteers (27 ± 8 years, body mass index 22.6 ± 2.4 kg/m 2 ) participated in a placebocontrolled, randomized, parallel double-blinded study. The intervention lasted for 6 months during which the subjects consumed mineral water 500 ml/day with (betaine group, n ¼ 32) or without (control group, n ¼ 31) a 4-g betaine supplementation.
Introduction
Betaine is a methylamine, which is formed from choline in the human body. It is an important methyl-group donor in methionine biosynthesis. Betaine is demethylated to form dimethylglycine and further sarcosine and glycine. Betaine has been used in animal nutrition for years. In humans, there is little safety data regarding the use of betaine in healthy individuals. In hyperhomocysteinemic patients, betaine is used to lower plasma homocysteine concentrations (Wilcken et al., 1983; Singh et al., 2004) , which is suggested to be an independent risk factor for coronary heart disease (El-Khairy et al., 1999; Chambers et al., 2000; Humphrey et al., 2008) . Hyperhomocysteinemia is also associated with hyperinsulinemia and insulin resistance, which in turn increases the risk of cardiovascular diseases (Meigs et al., 2001) . Low plasma betaine concentration, on the contrary, has been shown to be related to an unfavorable cardiovascular risk factor profile (Konstantinova et al., 2008) . In obese subjects, betaine has been found to decrease significantly plasma homocysteine concentration (Schwab et al., 2002) . In healthy individuals, orally administered betaine has been shown to result in a significant acute decrease in plasma homocysteine concentration (Schwab et al., 2006) . In a recent study, there was a tendency of betaine being associated with a memory improvement in elderly subjects (Eussen et al., 2007) .
In contrast to betaine's reported favorable effect on plasma homocysteine concentration, there are studies showing that betaine supplementation may cause an increase in serum low-density lipoprotein (LDL)-cholesterol concentration in healthy and obese (Schwab et al., 2002) subjects as well as in patients with chronic renal failure (McGregor et al., 2002) . Serum concentration of total triglycerides has also been shown to increase in some studies . These unfavorable effects on serum lipid profile may undo the favorable effect of betaine on plasma homocysteine concentration regarding the risk of cardiovascular diseases.
The aim of this study was to examine long-term effects of betaine on homocysteine metabolism, serum total and lipoprotein lipid concentrations, blood pressure, hemostatic factors and sensitive C-reactive protein (CRP) in healthy subjects without increased risk for atherosclerotic vascular diseases.
Subjects and methods

Subjects
Sixty-three non-obese (body mass index o27 kg/m 2 ) volunteers aged 20-50 years without atherosclerotic vascular diseases or metabolic disturbances and normal kidney, liver and thyroid functions were recruited by newspaper advertisements and from the students and the staff of the University of Kuopio. The subjects were free of any significant chronic disease that could have caused difficulties in following the study protocol. The exclusion criteria were body mass index 426.9 kg/m 2 , serum total triglyceride concentration 42 mmol/l, serum total cholesterol concentration 46 mmol/l, serum high-density lipoprotein (HDL)-cholesterol concentration o0.9 mmol/l or total-to-HDL-cholesterol ratio 45:1, symptomatic coronary heart disease, cancer, hypo-or hyperthyreosis, kidney or liver diseases, alcohol abuse (440 g/day), drug treatment for mental disturbances and lipid-lowering medication. The subjects were asked to discontinue possible consumption of fish oil or evening primrose oil capsules or any vitamin or mineral supplements 1 month before the beginning of the intervention. The baseline characteristics of the subjects are presented in Table 1 .
Products
The daily betaine dose was 4 g mixed with 500 ml of lowsodium mineral water. The subjects were advised to ingest the daily dose at least in two separate doses. The control group consumed low-sodium mineral water without betaine. The subjects followed their habitual diet during the study, and they were asked to keep their physical activity unchanged during the study.
Study design
The study was carried out according to a randomized, double-blinded parallel design. The subjects were matched for body weight, age and gender. Before the enrollment, the subjects gave their written informed consent. The study plan was approved by the Ethics Committee of the Hospital District of Northern Savo.
The length of the study was 6 months. The subjects visited the research unit at the beginning of the intervention (0 weeks) and at 4, 8, 12, 16, 20 and 24 weeks. Body weight and blood pressure was measured at each visit. Serum concentrations of total lipids and HDL and LDL cholesterol as well as plasma homocysteine concentration were measured at 0, 4, 8, 12 and 24 weeks. Plasma concentrations of sensitive CRP (hs-CRP), folate and vitamin B 12 , and serum Subjects filled in a questionnaire about physical activity, medication use and dietary supplements at the baseline and the end of the study. A 4-day food record was kept once before the beginning of the intervention and three times during the intervention preceding the visits at 4, 12 and 20 weeks.
Laboratory analyses
Blood samples were drawn after a 12-h overnight fast from an antecubital vein. Body weight was measured with a standardized electronic scale in light clothing. Height was measured at the beginning of the study in the Frankfurt position. Blood pressure was measured by a laboratory nurse and a sphygmomanometer was used. Two measurements in a sitting position 5 min apart were measured, and the mean was used for statistical analyses.
Plasma glucose concentration was analyzed with an enzymatic photometric method (Granutest 250, Diagnostica Merck, Darmstadt, Germany) and plasma insulin concentration with luminometric immunoassay (reagent ACS:180 IRI, Bayer A/S, USA, equipment ACS:180 PLUS, Bayer/Chiron, Tarrytown, NY, USA). Concentrations of serum total cholesterol and triglycerides were analyzed with the enzymatic colorimetric method using reagents Cholesterol CHOD-PAP and Triglycerides GPO-PAP (Roche Diagnostics, Mannheim, Germany) and KonePro Clinical Chemistry Analyzer (Thermo Clinical Labsystems, Konelab, Finland). HDL-cholesterol concentration was measured after dextransulphate-Mg 2 þ precipitation, with the same method as total cholesterol and triglyceride concentrations. Concentrations of apolipoprotein A-I and B were analyzed with an immunoturbidometric method (reagents Apolipoprotein A1 and Apolipoprotein B; Thermo Clinical Labsystems) using KonePro Clinical Chemistry Analyzer. Serum creatinine concentration was measured with an enzymatic method in the laboratory of Kuopio University Hospital. Concentration of oxidized LDL was measured as the baseline level of conjugated dienes in lipids extracted from LDL (Ahotupa et al., 1996) .
Betaine and dimethylglycine were analyzed as 4-bromophenacyl triflate derivatives according to the method by Lever et al. (1992) with modifications. 4-Bromophenacyl triflate was synthesized using the method described by Mar et al. (1995) . Calibration was performed by using the standard addition method by spiking a pooled serum sample with standards. The samples were prepared according to Lever et al. (1992) . The derivatives were separated using Chrompack Si column (3 mm, 150 Â 4.6 mm 2 , Chrompack, Middelburg, Netherlands). The mobile phase was 4 mmol/l triethanolamine-1.6 mmol/l citric acid in waterisopropanol (1:3).
Homocysteine was assessed by measuring concentrations of plasma homocysteine (tHcy). In addition, 24-h urine excretion of betaine and dimethylglycine were measured. Plasma folate and vitamin B 12 concentrations were measured as well, as they affect homocysteine metabolism. Plasma total homocysteine (tHcy) was determined by a modification of the high-pressure liquid chromatographic method described by Ubbink et al. (1991) . The modified mobile phase consisted of 0.37 mol/l acetate and 0.5 % methanol, pH 4.15. Plasma folate concentration was determined by the fluorescence polarization immunometric method (IMX; Abbott Laboratories, North Chicago, IL, USA). Plasma vitamin B 12 concentration was analyzed by the Quantaphase II B 12 radioassay (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Regarding hemostatic processes, factors included both in thrombotic and fibrinolytic processes were measured (factor VII, fibrinogen, D-dimer, PAI-1, von Willebrand factor). The analysis of the food records was performed using the Micro-Nutrica software, v. 2.5 (Rastas et al., 1997) , which is based on Finnish analyses and international food composition tables.
Statistical analyses SPSS statistical analysis software was used to perform the statistical analyses (v. 14.0, SPSS Inc., Chicago, IL, USA). The normal distribution of the variables was analyzed by the Kolmogorov-Smirnov test with a Lilliefors' correction. General linear model was used to analyze the interactions of time and group during the study. Paired samples t-test and Student's t-test were used for further analyses. Variables, which did not reach normal distribution after arithmetic procedures, were analyzed using Wilcoxon signed ranks test (comparisons within the groups) and Mann-Whitney's U-test (comparisons between the groups). Spearman's correlation coefficient was calculated for correlations and 
Results
In the betaine group, body weight was 64.7 ± 9.0 kg at 0 weeks and 64.5±9.0 kg at week 24. The respective values for body mass index were 22.6 ± 2.4 vs 22.5 ± 2.5 kg/m 2 , for systolic blood pressure 115 ± 7 vs 113 ± 7 mm Hg and for diastolic blood pressure 77±5 vs 72±7 mm Hg. The respective values in the control group were 65.7 ± 9.2 vs 66.3 ± 9.6 kg for body weight, 22.5 ± 2.2 vs 22.7 ± 2.2 kg/m 2 for body mass index, 117±7 vs 114±7 mm Hg for systolic blood pressure and 77 ± 5 vs 72 ± 7 mm Hg for diastolic blood pressure, respectively. There were no significant differences within or between the groups in these variables.
The food record data presented in Table 2 did not show any significant differences in nutrient intakes between the groups during the study.
Plasma betaine concentrations increased markedly in the betaine group during the first 8 weeks and stayed elevated until the end of the study. The concentration of plasma dimethylglycine, a metabolite of betaine, increased also in the betaine group. The excretion of betaine in urine increased in the betaine group as well (Table 3) . No changes in these variables were found in the control group. The correlation between plasma and urine betaine was r ¼ 0.005, P ¼ 0.970 at the beginning of the intervention and r ¼ 0.813, Po0.001 at the end of the intervention. The coefficients of reliability of plasma and urine betaine were calculated as well. Cronbach's a was 0.838 for plasma betaine and 0.022 for urine betaine.
The interaction of time and group was of borderline significance (general linear model, P ¼ 0.058) in plasma homocysteine concentration. It did not change in the betaine group (8.7±2.3 vs 8.4±1.5 mmol/l, 0 vs 24 weeks, respectively), but it tended to increase in the control group (8.9±3.3 vs 9.4±2.7 mmol/l, 0 vs 24 weeks, respectively, P ¼ 0.064), resulting in a 12% difference of a borderline statistical significance between the groups at the end of the study (P ¼ 0.097). Plasma hs-CRP concentration was 2.69±5.56 vs 1.74±1.89 mg/l in the betaine group and 1.59 ± 1.42 vs 2.54 ± 2.74 ml/l in the control group (0 vs 24 10.6 ± 3.1 10.5 ± 2.4 10.6 ± 2.5 10.9 ± 2.1 Polyunsaturated 5.2 ± 1.7 5.3 ± 1.5 5.4 ± 1.5 5.6 ± 1.2 Alcohol (E%) 2.6 ± 4.0 1.8 ± 2.9 4.5 ± 5.1 2.9 ± 3.7 Fiber (g) 21 ± 9 2 1 ± 8 2 4 ± 10 25 ± 10 Cholesterol ( Long-term effect of betaine U Schwab et al weeks, respectively) without a difference between or within the groups. In the concentrations of plasma cysteine, vitamin B 12 , folate or urate, no changes were found during the study in either of the groups (data not shown).
There was a significant interaction of time and group in the general linear model analysis in serum total and LDL-cholesterol concentrations and total-to-HDL-cholesterol ratio without a significant difference in further statistical analyses between or within the groups. Concentrations of HDL-cholesterol, triglycerides or oxidized LDL did not change during the study (Table 4) . Serum apolipoprotein A-I concentration increased in the betaine group, whereas no change was found in the control group. Apolipoprotein B concentration did not change during the study (Table 4) .
Regarding hemostatic factors, there was a significant (P ¼ 0.035) interaction of time and group in plasma fibrinogen concentration without a significant difference between or within the groups in further statistical analyses (betaine group 3.2 ± 0.6 vs 3.3 ± 0.7, control group 3.1 ± 0.7 vs 3.0 ± 0.4 g/l, 0 vs 24 weeks, respectively). PAI-1 concentration increased significantly in the betaine group (7.19±2.91 vs 8.85±3.78 AU/ml, 0 vs 24 weeks, P ¼ 0.028), resulting in a significantly higher concentration in the betaine group as compared with the control group at the end of the study (8.85 þ 3.78 vs 6.25±2.38 AU/ml, 0 vs 24 weeks, P ¼ 0.006). The proportion of plasma factor VII or serum D-dimer concentration did not change during the study (data not shown).
Regarding the safety parameters, there were no changes in the concentrations of serum creatinine, g-glutamyltransferase or alanine aminotransferase (data not shown). There was a significant interaction of time and group (P ¼ 0.007) in blood hemoglobin concentration without significant differences between or within the groups in further statistical analyses (betaine group 137±12 vs 130±13, control group 132 ± 13 vs 131 ± 12 g/l, 0 vs 24 weeks, respectively). Blood hematocrit or number of leucocytes or thrombocytes did not change during the study (data not shown).
Discussion
The present study was planned to give pertinent information about the long-term effects of betaine on several risk factors of atherosclerotic vascular diseases (serum total and lipoprotein lipid concentrations, blood pressure, plasma homocysteine concentration and hemostatic factors) and to assess the safety of long-term betaine intake in healthy subjects.
The increase in plasma betaine concentration and urine betaine excretion found in this study indicated excellent compliance of the subjects during the study, as the changes found in these variables in the betaine group are impossible to reach without betaine supplementation. Plasma concentrations are usually about 30 mmol/l, ranging from 9 to 90 mmol/l . However, the intra-individual variability is small without betaine supplementation (Lever et al., 2004) .
In some studies, betaine supplementation has been shown to increase serum LDL-cholesterol concentrations in healthy subjects , subjects on a weight-loss diet (Schwab et al., 2002) and also in subjects with chronic renal failure (McGregor et al., 2002) . The mechanism by which betaine might increase serum LDL-cholesterol concentration has been proposed to be the increased synthesis and export of lipids in VLDL from the liver into the circulation. This same mechanism is suggested to be behind the finding that betaine attenuates the development of alcoholic fatty liver in rats (Kharbanda et al., 2009 ) and decreases lipid accumulation in the liver in a transgenic mice model on hyperhomocysteinemia (Schwahn et al., 2007) . In the present study, betaine supplementation did not increase serum LDL-cholesterol concentration statistically significantly. The concentration of apolipoprotein B, which is the only apolipoprotein of LDL, did not change in the betaine group, indicating that the number of LDL particles did not change either. The reason for a statistically non-significant finding Long-term effect of betaine U Schwab et al in this study regarding serum LDL-cholesterol concentration might be due to the normal lipid profile of the subjects, and the fact that the subjects were healthy and quite young. The possible increase in VLDL output from the liver may not cause a clinically measurable outcome in this kind of a group of subjects. Betaine supplementation has been reported to have both acute (Schwab et al., 2006) and longer term (Schwab et al., 2002; Steenge et al., 2003) lowering effect on plasma homocysteine concentration in humans. Doses in the range of dietary intake are also effective (Olthof et al., 2003) . Unlike previous results, plasma homocysteine concentration did not decrease significantly in the betaine group in this study. However, in the control group, plasma homocysteine concentration increased. This increase in plasma homocysteine concentration might be explained by the seasonal variation. So, the betaine supplementation might have prevented the increase of plasma homocysteine concentration found in the control group, resulting in a somewhat lower plasma homocysteine concentration in the betaine group at the end of the study. Furthermore, it is noteworthy that the plasma homocysteine concentration of the subjects was at the lower range. It has been shown that the association of betaine with fasting plasma homocysteine concentration is more pronounced in subjects with lowserum folate concentration . Furthermore, folic acid supplementation has been shown to increase plasma betaine concentration (Melse-Boonstra et al., 2005) . In the present study, the nutrient intake analysis showed the folate intake being close to the level recommended for men (300 mg/day), whereas the recommendation for women in fertile age (400 mg/day) was not reached.
Inflammation is included in the atherosclerotic process and hs-CRP is a marker of low-grade systemic inflammation (Pradhan and Ridker, 2002) . In the present study, betaine was found to have no effect on hs-CRP. In a recent cross-sectional survey, betaine intake was found to be negatively associated with CRP, tumor necrosis factor-a and interleukin-6 (Detopoulou et al., 2008) . In the rather young subjects participating in the present study, changes in indicators of low-systemic inflammation might be difficult to detect. Regarding hemostatic factors, betaine was not found to have any effect except an increase in PAI-1 concentration in the betaine group. Increased PAI-1 concentration may slow down the fibrinolytic process. The levels of PAI-1 were quite low in the present study, and the clinical significance of low levels in healthy subjects may be considered to be of limited value.
The safety parameters including blood count, and concentrations of serum creatinine, alanine aminotransferase and g-glutamyltransferase indicated no adverse effects by the use of betaine. Betaine has been reported to lower hepatic steatosis in patients with non-alcoholic steatohepatitis and reduce liver transaminases, for example alanine aminotransferase and g-glutamyltransferase (Miglio et al., 2000; Abdelmalek et al., 2001) . Betaine serves as a lipotrope, that is prevents or reduces accumulation of fat in the liver (Craig, 2004) . In rats, betaine has been shown to protect the liver from oxidative stress and steatosis. The mechanism might be its effect on the transsulfuration reactions (Kwon et al., 2009 ).
In conclusion, betaine supplementation did not have a significant effect on serum lipid profile, and it is safe in a long-term use in healthy subjects.
